NICM
IMNM icon

Neo Ivy Capital Management’s Immunome IMNM Stock Holding History

Neo Ivy Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71M Buy
+80,876
New +$1.73M 0.39% 100
2026
Q1 		– Sell
-192,635
Closed -$4.14M – 416
2025
Q4 		$4.14M Buy
+192,635
New +$3.38M 0.65% 49

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Neo Ivy Capital Management's IMNM Position: Q2 2026 in Review

Neo Ivy Capital Management opened a new position in Immunome (IMNM) in Q2 2026: 80,876 shares worth $1.71M. The stake represents 0.39% of the portfolio and ranks #100 among its holdings. This is a return to the name: Neo Ivy Capital Management previously reported a position in IMNM as recently as Q4 2025.

Neo Ivy Capital Management first reported a position in IMNM in Q4 2025 and has held it in 2 quarters since. The position peaked at $4.14M in Q4 2025. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Neo Ivy Capital Management held 80,876 shares of Immunome worth $1.71M as of Q2 2026.
  • Immunome was a new Neo Ivy Capital Management position in Q2 2026.
  • Immunome made up 0.39% of Neo Ivy Capital Management's portfolio in Q2 2026, its #100 holding.
  • Neo Ivy Capital Management first reported a position in Immunome in Q4 2025 and has held it in 2 quarters since.
  • Neo Ivy Capital Management's Immunome position peaked at $4.14M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.